+ Foxp3 + T regulatory (Treg) cells can promote transplantation acceptance across major histocompatibility complex (MHC) barriers, while myeloid-derived suppressor cells (MDSCs) inhibit effector Tcell responses in tumor-bearing mice. One outstanding issue is whether combining the potent suppressive function of MDSCs with that of Treg cells might synergistically favor graft tolerance. In the present study, we evaluated the therapeutic potential of MDSCs and natural Treg cells in promoting allograft tolerance in mice by utilizing immunomodulatory agents to expand these cells in vivo. Upon administration of recombinant human granulocyte-colony stimulating factor (G-CSF; Neupogen), or interleukin-2 complex (IL-2C), Gr-1 + CD11b + MDSCs or CD4 + Foxp3 + Treg cells were respectively induced at a high frequency in the peripheral lymphoid compartments of treated mice. Interestingly, induced MDSCs exhibited a more potent suppressive function in vitro when compared to MDSCs from naive mice. Furthermore, in vivo coadministration of Neupogen and IL-2C induced MDSCs at percentages that were higher than those seen when either agent was administered alone, suggesting an additive effect of the two drugs. Although treatment with either IL-2C or Neupogen led to a significant delay of MHC class II disparate allogeneic donor skin rejection, the combinatorial treatment was superior to either alone. Importantly, histological assessment of surviving grafts revealed intact morphology and minimal infiltrates at 60 days posttransplant. Collectively, our findings demonstrate that concurrent induction of MDSCs and Tregs is efficacious in downmodulating alloreactive T-cell responses in a synergistic manner and highlight the therapeutic potential of these naturally occurring suppressive leukocytes to promote transplantation tolerance.
INTRODUCTION
within the tumor microenvironment and either persistence or progression of tumor growth (29, 33) . In human studies, equivalent populations of cells have also been Tumorigenesis is a complex phenomenon that has been studied utilizing animal models with the attempt reported in cancers such as head and neck squamous cell carcinoma (3). to understand its pathogenesis. Once established, tumors utilize several strategies to evade recognition by the imDepending on the model of investigation, MDSCs have been described as expressing various cellular markmune system (8, 42) . One such strategy is the recruitment of myeloid-derived suppressor cells (MDSCs) through ers (15) . In mice, they are typically contained in the CD11b + leukocyte subset and express varying levels of granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte-colony stimulating factor (GGr-1 (Ly6G/C), a cell surface molecule with heterogeneous distribution that is used to delineate their differen-CSF) that is produced by tumor cells (15, 42) . The prevalence of these suppressor cells in and around the tumor tiation stages (7,50). They also express F4/80 (23) , and interleukin-4 receptor α (IL-4Rα) (12,16). Unlike conmicroenvironment consequently contributes to tumor escape, as several animal models have demonstrated a corventional CD11b + macrophages, these cells express low levels of major histocompatibility complex (MHC) class relation between increased frequencies of these cells II, CD40, and B7.1/2 costimulatory molecules, a phenoAntibodies and Fluorescent Activated Cell Sorter (FACS) Analysis type that is distinct from that of immature and mature antigen-presenting cells (4, 41, 51) . The potent suppress-FITC-conjugated monoclonal antibodies (mAbs) to ive activity of MDSCs is revealed by in vitro studies in CD4 (Gk1.5), Gr-1 (RB6-8C5), CD40 (HM40-3), CD80 which they effectively inhibit the proliferation of either (GL1), IA/E (NIMR-4), F4/80 (BM8), phycoerythrin antigen-or mitogen-activated T lymphocytes (16, 43) .
(PE)-conjugated mAbs to Gr-1 (Ly6C/6G), CD11b (M1/ As the understanding of the mechanisms by which 70), CD124, peridinin chlorophyll protein complex MDSCs suppress effector immune responses is gradu-(PerCP)-anti Gr-1 (RB6-8C5), allophycocyanin (APC)-ally unfolding, certain key proteins have been identified conjugated CD11b (M1/70), and CD25 (PC61) were all as crucial to their suppressive function. For example, expurchased from BD Pharmingen (San Diego, CA). PEpression of IL-4Rα is paramount to arm MDSCs with anti-Foxp3 (FJK16s) was obtained from eBiosciences the ability to function as suppressors, with the most po-(San Diego, CA) and was used in intracellular FACS tent cells residing within the Ly-6C-high subset (11, 16) .
analysis following the manufacturer's instructions. In addition, these cells express high levels of nicotin-FACS analysis was performed using FACs Calibur and amide adenine dinucleotide phosphate (NADPH), phagoCellQuest software. For cultured cells, 7AAD dye was cytic oxidase (heme oxygenase-1), nitric oxide synthase utilized to exclude dead cells from the analysis. Typi-(NOS2), and arginase-1, enzymes that are involved in cally 30,000-50,000 events were collected per sample. processes that lead to the production of nitric oxide
Cell Purification and In Vitro Studies (NO), peroxynitrite, reactive oxygen species (ROS), or to the depletion of the semiessential amino acid L-argiTo isolate unfractionated T cells, spleen cell suspennine (9,24,25,46). The resulting metabolites affect T-cell sions were maintained in complete RPMI-1640 medium intracellular signaling by lowering the CD3-ζ chain, supplemented with 5% fetal calf serum (FCS). Cells blocking IL-2R activated pathways, changing the affinwere washed twice with Hank's balanced salt solution ity of the T-cell receptor (TCR)/MHC peptide complex, (HBSS) and incubated with Thy1.2 magnetic-activated or inducing apoptosis (6,13,34, 36, 38, 40) .
cell separation (MACS) microbeads, respectively, in Although there are extensive studies on the role of HBSS containing 5% FCS and 2 mM EDTA for 15 min MDSCs in downmodulating immunity in tumor models, at 4°C. After incubation, cells were positively selected little is known about their role in nontumor settings.
on MS MACS separation columns (Miltenyi, Biotec, While it is well established that natural CD4 + Foxp3 + Auburn, CA). MDSCs from normal or Neupogen-treated Treg cells are efficacious at promoting tolerance across mice were purified from spleen cell suspensions after MHC barriers in bone marrow and solid tissue transincubating with PE-conjugated Gr-1 and anti-PE miplantation settings, there are scant data about the role crobeads using a similar protocol as above. For carboxyof MDSCs in modulating time and/or severity of graft fluorescein succinimidyl ester (CFSE) dilution assays, rejection. In recent reports, MDSCs were implicated in purified T cells were labeled with CFSE at 2.5 µM conanimal models of kidney allograft tolerance (12) and centration and incubated at 37°C for 10 min. Cells (1 × were also found to delay rejection of antigen-mismatched 10 6 ) were cultured with 1 × 10 6 antigen-presenting cells skin grafts (10,53). Given their potent inhibitory effect (APCs) (T-cell depleted, mitomycin-treated splenocytes) in tumor-bearing mice, one outstanding issue is whether in the presence or absence of 50 µl anti-CD3 supernatant combining the potent suppressive function of both natu-(2C11) in 24-well plates for 48 h. MDSCs were then ral CD4 + Foxp3 + Treg cells and MDSCs might favor added at 1:1 ratio to responding T cells. In other experitransplantation tolerance. Thus, the present study was ments, purified T cells were isolated from naive BALB/ designed to evaluate the therapeutic potential of MDSCs c mice, or mice treated with Neupogen and/or IL-2 comand natural Treg cells in promoting allograft tolerance plex and then incubated with C57BL/6 APCs (1 × 10 6 ) by utilizing immunomodulatory agents to expand these in the presence or absence of MDSCs (as indicated) obcells in vivo.
tained from Neupogen-treated mice. 
MATERIALS AND METHODS
In Vivo Mouse Studies Mice C57BL/6, BALB/c, C3H/HeJ, and B6(C)-H-2-Mice were injected daily with recombinant human G-CSF (Neupogen, Amgen Inc., Thousand Oaks, CA at 5 AB1bm12/KhEgj were obtained from Jackson Laboratory (Bar Harbor, ME). All experiments were approved µg/mouse) subcutaneously (SC) once a day for 5-14 days unless otherwise specified. G-CSF was diluted in by the Institutional Animal and Use Committee (IACUC) at the University of Miami and performed fol-5% dextrose and 1% mouse serum albumin (vehicle).
As control, mice received vehicle or PBS. IL-2 complex lowing the IACUC guidelines.
(IL-2C) containing 0.5 µg recombinant mouse IL-2 regimen was then utilized to determine whether chronic treatment affects the duration of MDSCs induction and (eBioscience, San Diego, CA) and 5 µg rat anti-mouse IL-2 (JES6-12A1, R&D Systems, MN) in 100 µl PBS persistence. Upon analysis, elevated levels of MDSCs could be observed in the spleen of treated mice for more was injected into the peritoneal cavity of each mouse for 5 consecutive days and twice a week thereafter (48) than 1 week after cessation of the 14-day administration regimen (Fig. 1E ). These data indicate that Gr-1 + CD11b
+ throughout the duration of the study for skin graft recipients. Skin grafting was performed as previously decells are effectively induced in mice using recombinant human G-CSF and highlight how chronic administration scribed (1) MDSCs from Neupogen-treated mice than that on all compared groups at indicated confidence levels to MDSC from naive mice ( Fig. 2A , B, Table 1 ), suggestfurther evaluate the validity of the significance in differing that Neupogen not only expanded MDSCs but also ences as measured by the Student's t-test.
induced their activation. We also found that expression of the CXCR2 and CCR4 chemokine receptors was RESULTS much higher on MDSC from treated mice, consistent
In Vivo Administration of Human Recombinant G-CSF
with the idea of systemic recruitment and trafficking that (Neupogen) Induces MDSCs in Mice result in higher frequencies at multiple peripheral sites (data not shown). These data suggest that Neupogen adTo begin to investigate whether these suppressor cells are efficacious in promoting tolerance to alloantigens, ministration not only increases MDSCs number but could also favor their maturation towards a more supwe treated mice with recombinant human G-CSF (Neupogen), the administration of which has been reported pressive phenotype. to increase the fraction of cells that express Gr-1, one of
Inhibition of T-Cell Response by Neupogen-Induced MDSCs the phenotypic markers of MDSCs (37). A short course (5 days) of treatment with different doses of Neupogen
We then sought to determine whether MDSCs from Neupogen-treated mice are functionally capable of supled to induction of Gr-1
+

CD11b
+ cells in the spleen of BALB/c recipient mice, which was remarkable at the 5 pressing polyclonal and alloreactive T-cell responses. Unfractionated T cells stimulated with anti-CD3 prolifand 10 µg dosage 1 day posttreatment ( Fig. 1A-C ). This effect was transient, as only modest increase above conerate extensively as revealed by CFSE dilution of both the CD4 + and CD8 + subsets within 3 days of culture trol levels in the MDSC frequency was noted at 3 and 7 days after treatment (Fig. 1A, C) . From these data, we (Fig. 3A) . This proliferative response is inhibited upon addition of MDSCs isolated from Neupogen-treated determined that a dosage of 5 µg/recipient was optimal at inducing MDSCs and was chosen for subsequent mice with many responder cells (ϳ38%) having undergone only one or two rounds of cell division (Fig. 3A) . treatments. To further evaluate the efficacy of in vivo Neupogen administration, we analyzed, concurrently,
The addition of spleen cells, in contrast, failed to yield similar outcomes, demonstrating that the MDSCs supmultiple tissues including peripheral blood, spleen, bone marrow ( Fig. 1D) , and lymph nodes (data not shown).
pression is unlikely due to nonspecific depletion of growth factors in the cultures. To further evaluate Similar to the spleen, significant increases in the fraction of Gr-1 + CD11b + MDSCs were observed. As this induc-MDSC suppressive function, we set up a mixed leukocytes reaction (MLR) in the presence or absence of tion appears to be short lived, a 2-week daily injection MDSCs. Analysis of T-cell cultures stimulated with althe suppressive capacity of Neupogen-induced MDSCs both in a polyclonal antigen stimulation setting and in logeneic APCs revealed a significant reduction (p = 0.001) in proliferation of responder cells in the presence an alloreactive response, which is highly relevant in transplantation settings. of MDSCs, while addition of control syngeneic spleen cells resulted in higher proliferative responses (Fig. 3B) . 18,20,26,31) (Fig. 3B, C) , we hypothesized that increasperiments with mice treated with Neupogen and/or IL-2C utilizing donor skin that is disparate in only the ing their numbers in vivo by administration of Neupogen (for MDSCs) or IL-2C (for Treg cells) (48) , alone MHC class II constituents (i.e., bm12 to C57BL/6) as well as unrelated third party that is both MHC class I or in combination might downregulate antidonor immunity and tip the balance in favor of tolerance. To test and II disparate (i.e., C3H to C57BL/6). In C57BL/6 recipients, treatment with Neupogen (Fig. 4B) (Fig. 5A) . Administration of IL-2C pared to the control PBS-treated group (Fig. 4A) . Interestingly, the administration of the IL-2 complex also dealone or in combination with Neupogen, however, led to expansion of CD4 + Foxp3 + Treg cells in these periphlayed significantly (p = 0.002) the loss of bm12 donor skin (MST of 50 vs. 20 days for controls) (Fig. 4C) , eral sites when compared to PBS controls (Fig. 5A) . While Neupogen alone resulted in an elevation of an effect that was even more pronounced when it was combined with Neupogen (MST of 74) (p = 0.0032) MDSC fraction in treated mice, the percentage of MDSCs was not affected in mice treated with IL-2 complex, sug- (Fig. 4D) . Although the rejection of fully allogeneic C3H donor skin was comparable in all groups, these gesting that the latter acts specifically to promote the expansion of Treg cells and not MDSCs (Fig. 5B ). Interdata highlight an effect of the combinatorial treatment in promoting prolonged survival across limited MHC estingly, an additive effect was noted for MDSC fractions in mice treated with a combination of both IL-2 barriers when the two naturally occurring suppressor cell subsets are induced to elevated levels in the periphery.
In Vivo Induction of MDSCs and Treg Cells Promotes
complex and Neupogen in all three compartments ( Kinetics of skin graft rejection in an MHC class II disparate skin graft model. Eightto12-week-old C57BL/6 mice received three contiguous skin grafts from C57BL/6, B6bm12, and C3H donor mice, respectively. Mice were then treated with Neupogen (5 µg) and/or IL-2 complex daily for the first 5 days beginning at day 0 and thereafter three times a week for Neupogen or twice a week for IL-2 complex throughout the duration of experiment. The control group received PBS. All recipient mice were monitored every other day until graft rejection, defined as >80% loss of tissue. Kinetics of graft rejection for MHC class II disparate bm12 donor skin and full MHC mismatch C3H donor skin in control C57BL/6 or treated recipients is shown. Treatments and the mean survival time (MST) of allogeneic skin grafts are listed within each panel of the figure. of α-CD3. Upon analysis, the proliferative response of ing (H&E) on donor bm12 skin tissues that were excised from C57BL/6 transplant recipients treated with PBS T cells derived from all groups as indicated after polyclonal stimulation was comparable (Fig. 5C ). In MLR (controls), Neupogen, and/or IL-2C. Analysis at day 12 posttransplant revealed that in the control PBS group responses, however, proliferation by T cells obtained from mice treated with both Neupogen and IL-2 comthere was massive cellular infiltration and tissue damage, which precedes graft loss between 15 and 20 days plex was significantly reduced in contrast to that of T cells obtained from mice treated with PBS, Neupogen, for rejecting control mice. In contrast, intact epidermis, hair follicles, and minimal infiltrates were observed in or IL-2 complex alone (Fig. 5D) . These data suggests that alloantigen-reactive T-cell subsets in mice treated all experimental mice (Fig. 6A) . Remarkably, at 60 days posttransplant, 2/4 of the mice treated with IL-2 comwith both agents remained in a somewhat suppressed state ex vivo and thus only partially responded to alloanplex and 4/5 of the mice treated with Neupogen/IL-2 complex still retained 50-70% of donor graft (data not tigen stimulation.
One of several mechanisms that is implicated in shown). Histological evaluation of bm12 graft retrieved from these mice at day 60 posttransplant revealed mod-MDSC-mediated suppression of antitumor immunity is the downregulation of the ζ chain of the CD3 complex erate infiltration, but with a mostly intact epidermal layer and preserved hair follicles, suggesting minimal that results in diminished activation of tumor-specific T cells (15) . Due to the prevalence of high fractions of pathological damage to the overall tissue (Fig. 6B) . Taken together, these data further support the overall MDSCs in mice treated with Neupogen, we investigated whether this mechanism is operative in our system. observation that loss of bm12 donor skin is delayed in treated mice, possibly due to inhibition of effector cell After a short course of Neupogen and/or IL-2 complex treatment, analysis of the splenic T cells revealed a infiltration into the graft or impairment of effector function at the graft site. downregulation of the ζ chain in Neupogen or IL-2 complex-treated mice that was more striking with the combi-DISCUSSION nation of the two agents (Fig, 5E, F) . This result is consistent with the diminished alloreactive responses by T Current treatments for restraining the immune responses against allografts often utilize strong immunocells from treated mice and supports the notion that impaired T-cell activation resulting from suboptimal CD3 suppressive biological agents that can sometimes lead to damaging side effects and generate a global depression signaling likely contributes to lowered T-cell proliferation. of the immune system. As various regulatory and/or suppressor cells that target multiple immune perturbaHistological Assessment of Skin Grafts Reveals tions are being uncovered, there is increasing interest in Markedly Reduced Cellular Infiltration the utilization of such naturally occurring suppressive in Treated Recipients cells as therapeutic alternatives to promoting transplantation tolerance. Herein, we explored the potential of In addition to visual evaluation and scoring of donor skin grafts, we performed hematoxylin and eosin staintwo suppressive leukocyte subsets, CD4 Figure 5 . Induction of MDSCs and CD4 + Foxp3 + Treg cells upon coadministration of Neupogen and IL-2 complex. C57BL/6 skin transplant recipients as described in Figure 4 were sacrificed at time of graft rejection and the peripheral blood, spleen, and lymph nodes (LN) were utilized for multicolor FACS analysis to determine the fraction of CD4 + Foxp3 + or Gr-1 + CD11b + cells. Summary of (A) CD4 + Foxp3 + Treg or (B) Gr-1 + CD11b + MDSC percentages in the peripheral blood (PB), spleen (SPLN), and lymph nodes (LN) in the groups that received the indicated treatments. (C, D) C57BL/6 mice were treated for 5 consecutive days with Neupogen and/or IL-2 complex, followed by a maintenance dose of Neupogen (three times) and/or IL-2 complex (twice) for 1 week. Three days after last treatment, mice were sacrificed and T cells (1 × 105) purified from the spleens of these mice were cultured with BALB/c (left) or C3H (right) APCs in the presence (C) or absence (D) of α-CD3 for 3 or 4 days, respectively, in 96-well round bottom plates. Thymidine was added to the triplicate wells in the last 18 h of culture. Summary of T-cell proliferation based on thymidine incorporation from one representative of two independent experiments is shown. p-Values for statistically significant difference between the indicated pairs of experimental groups as determined by Student's t-test are shown (p < 0.05) and the difference between the IL-2C and IL-2C + Neu in mice cultured with C3H APCs remained statistically significant (and other values were nearly significant) after performing Bonferroni correction test for comparisons to the IL-2C + Neu group at a 0.0167 significance level. and myeloid-derived suppressor cells, to facilitate tolermay be instrumental in creating a "tolerogenic" environment. Thus, treatments targeted at induction or traffickance in a murine model of MHC disparate skin transplantation. A key finding in this study is that donor skin ing of MDSCs to lymph nodes need to be explored. Of note is that our choice of human G-CSF for these experigraft rejection is significantly delayed when the fraction of these two regulatory cells are increased in circulation ments is in part based on our findings that both mouse and human G-CSF were superior in inducing MDSCs in as potentiated by IL-2 complex and recombinant human G-CSF.
vivo compared to GM-CSF (data not shown). We chose human G-CSF for these experiments due to its ready In many experimental tumor models, a high fraction of MDSCs are observed in the tumor microenvironment availability and its potential use in additional investigations that may utilize human cells in a murine model. and this correlates with an abundance of immunomodulatory cytokines such as G-CSF, GM-CSF, and IL-10, Although the dose of the human G-CSF utilized in this study is higher than currently administered in patients which are secreted by tumor cells demonstrating the role of these biological agents in the recruitment of MDSCs after chemotherapy, it is important to reiterate that our investigations were performed in mice. So, the observa-(15,29). Our finding that administration of recombinant human G-CSF (Neupogen) led to several fold induction tion that mouse G-CSF induced levels of MDSCs that were higher than human G-CSF in one of our limited of MDSCs in multiple tissues supports such observations and is consistent with reports of others where GMexperiments (not discussed) is not surprising. Thus, we have reason to believe that current clinical dosage of CSF and/or G-CSF have been utilized to mobilize cells of the myeloid lineage in rodents (28, 37, 43) . Although Neupogen or even lower may be efficacious for promoting the induction of MDSCs in humans due to specie significant large numbers of MDSCs relative to unmanipulated animals were measured in the peripheral blood, specificity. Moreover, because interindividual differences may exist in the metabolism and catabolism of spleen, and bone marrow, the fold increase is less dramatic and somewhat unremarkable in the lymph nodes.
this cytokine (32), further studies in humans are necessary to establish the minimal dose of Neupogen capable As a critical site for T-cell priming, lymph node MDSCs of mobilizing and differentiating MDSCs for therapeutic sponse that, for instance, correlates with the ex vivo analysis of CD3 ζ chain expression on T cells isolated purposes.
An outstanding issue is whether the induced MDSCs from treated mice, it is somewhat contradictory to the in vivo observations in which C3H donor skin graft was are different in phenotype and function from the naturally occurring cells. Given the heterogenicity of MDSCs, not delayed in mice treated with both Neupogen and IL-2 complex. Our in vitro study represents an isolated we cannot rule out the possibility that other minor immature myeloid progenitor cellular subsets reside within event involving alloreactive T-cell response, particularly, through the direct allorecognition pathway. In the induced population. Nevertheless, it is quite clear from our assessments that the induced MDSCs are vivo, however, multiple effector mechanisms have been implicated in acute and/or chronic graft rejection. Belargely similar in phenotype to the typical Gr-1 + CD11b
+ cells in naive mice. The higher expression of IL-4Rα sides the indirect pathway, which is also crucial for chronic graft rejection, there is growing evidence that expression on the former, however, may indicate a more potent suppressive function, consistent with the observasome humoral (high-affinity alloantibodies) and even innate (NK cells) immune response contribute to graft retion that MDSCs from Neupogen-treated mice inhibited T-cell proliferation better than those derived from naive jection (22, 30) . Thus, the apparent disparity between depressed alloreactive T-cell response in vitro and the mice when tested in an MLR (Fig. 3C ). Our evaluation of the induced MDSCs in the present study also revealed absence of a delay in fully allogeneic donor graft may likely be explained by such additional effector mechathey express little to no MHC class II molecules and other canonical costimulatory molecules, and, as such, nisms that regulatory cells need to overcome to promote tolerance. are unlikely to function and contribute to professional and classical antigen presentation and T-cell activation.
It is unclear at present whether this conditioning regimen results in a generalized immunosuppression similar Although we previously showed (44), using a transgenic system, that MDSCs can cross-present antigen specifito drugs that are currently utilized to dampen the immune response in transplantation settings or if it is a cally to Tregs, it is extremely difficult to confirm or deny this hypothesis in this experimental setting because graft specific anergy. Our findings demonstrate that these treatment regimen are unlikely to induce a "wholesale" skin alloantigens are unknown and CD4 T cells with this particular specificity are not easily detectable.
anergy as proliferation to polyclonal stimulator was only minimally diminished in vitro within the bulk T-cell Our data indicate that both CD4 + and CD8 + T cells were effectively suppressed in the presence of polypopulation. Although the mechanisms of MDSC suppression in this study are yet to be elucidated, it remains clonal anti-CD3 stimulation, consistent with the report by De Wilde et al. (10). The capacity of these MDSCs a possibility that the induced MDSCs may modify T-cell phenotype, using mechanisms dependent on L-arginine to prevent alloantigen-mediated T-cell response was demonstrated in an MLR and further extended to in vivo metabolism and/or disrupting the CD3 complex (14, 15, 35, 39, 45, 47, 49) , which ultimately results in lowered efstudies where MHC class II disparate bm12 donor skin graft rejection was delayed significantly in the presence fector function. The finding that the ζ chain expression by T cells within the spleen of mice treated with either of induced MDSCs. In naive mice, the kinetics of allogeneic skin graft rejection is not altered even in the presNeupogen or more remarkably in combination with IL-2 complex is downregulated is consistent with this ence of a small fraction of circulating MDSCs, suggesting that utilization of these cells to favor transplantation notion. It remains to be determined the possible involvement of Treg cells in this process as IL-2 complex treattolerance will likely require protocols geared at expanding their numbers in vivo. Our findings thus provide ment, similar to Neupogen treatment alone, led to lower expression of the ζ chain. Alternatively, MDSCs may some proof of principle to achieving such goals, at least in a somewhat stringent animal model of MHC-mismatched induce the apoptosis of some of the alloreactive T cells that are in proximity within a microenvironment (15) transplantation. Interestingly, combinatorial treatment that also increases the frequency of CD4 + Foxp3 + Treg and this may explain the significantly depressed proliferative response by T cells from treated mice. Another cells in parallel with MDSCs strikingly led to more robust delay of MHC class II disparate donor skin, sugpossibility is that when present in higher than normal frequencies within a niche, they may competitively pregesting an additive suppressive effect on host alloreactive T cells. Consistent with this idea, T cells isolated vent APCs from gaining sufficient access to T cells, thus increasing the threshold required for optimal T-cell actifrom mice treated with both IL-2 complex and Neupogen proliferate less in the presence of allogeneic APCs vation and differentiation. Although we favor the idea that our approach utilizing pharmacologic agents to inwhen compared to those derived from mice receiving single treatments (Fig. 5D ). Although this in vitro findduce MDSCs and Tregs in vivo may be less harsh on the immune system than commonly used immunosuping suggests some attenuation of alloreactive T-cell re- der way to evaluate these possibilities.
